CANASA® (Mesalamine, USP) Rectal Suppository 1000 mg

Mesalamine is the active therapeutic component in CANASA®1 and each rectal suppository contains 1000 mg of mesalamine (USP) in a base of hard fat, NF1

Indicated for the treatment of active ulcerative proctitis1

Should be taken once daily at bedtime. The suppository should be retained for one to three hours or longer, if possible, to achieve the maximum benefit.1

Usual course of therapy is from 3-6 weeks depending on symptoms and sigmoidoscopic findings1

    - Studies suggest that use of CANASA® suppositories following a 6-week short
       term treatment regimen will delay relapse1



Information on this website is not intended to replace the advice of your physician(s). Please consider what you learn here a starting point for a conversation with your physician. All care of ulcerative proctitis and related conditions must be guided by the appropriate healthcare professional. CANASA® is a prescription drug.

Reference
1.CANASA® (Mesalamine, USP) Rectal Suppository 1000 mg Prescribing Information, October 2008.

 

CANASA® is available by prescription only.

CANASA® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis.

CANASA® is contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated fatty acid esters (Hard Fat, NF)], or to salicylates (including Aspirin).

As with other mesalamine containing products, less common but possibly serious side effects such as acute intolerance syndrome, pericarditis and pancolitis may occur.

Patients on CANASA® 1000 mg, especially those on concurrent oral products which contain or release mesalamine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.

Caution should be exercised when CANASA® suppositories are initially used in patients known to be allergic to sulfasalazine.

CANASA® was generally well tolerated in clinical studies. The most common side effects of CANASA® are dizziness (3%), rectal pain (1.8%), fever (1.2%), rash (1.2%), acne (1.2%), and colitis (1.2%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.